2026-04-14T07:59:57Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1579592025-12-06T04:04:59Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis Shah, Nirav N. Ahn, Kwang Woo Litovich, Carlos Fenske, Timothy S. Ahmed, Sairah Battiwalla, Minoo Bejanyan, Nelli Dahi, Parastoo B. Bolaños Meade, Javier Chen, Andy I. Ciurea, Stefan O. Bachanova, Veronika DeFilipp, Zachariah Epperla, Narendranath Farhadfar, Nosha Herrera, Alex F. Haverkos, Bradley M. Holmberg, Leona Hossain, Nasheed M. Kharfan-Dabaja, Mohamed A. Kenkre, Vaishalee P. Lazarus, Hillard M. Murthy, Hemant S. Nishihori, Taiga Rezvani, Andrew R. D'Souza, Anita Savani, Bipin N. Ulrickson, Matthew L. Waller, Edmund K. Sureda, Anna Smith, Sonali M. Hamadani, Mehdi Cèl·lules canceroses Malaltia de Hodgkin Cancer cells Hodgkin's disease The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we report allo-HCT outcomes of NHL patients aged ≥65 years (older cohort; n = 446) compared with a cohort of younger NHL patients aged 55-64 years (n = 1183). We identified 1629 NHL patients undergoing a first reduced-intensity conditioning (RIC) or nonmyeloablative conditioning allo-HCT from 2008 to 2015 in the United States. Cord blood or haploidentical transplants were excluded. The median age was 68 years (range 65-77) for the older cohort vs 60 years (range 55-64) in the younger cohort. The 4-year adjusted probabilities of nonrelapse mortality (NRM), relapse/progression (R/P), progression-free survival (PFS), and overall survival (OS) of the younger and older groups were 24% vs 30% (P = .03), 41% vs 42% (P = .82), 37% vs 31% (P = .03), and 51% vs 46% (P = .07), respectively. Using multivariate analysis, compared with the younger group, the older cohort was associated with increased NRM, but there was no difference between the 2 cohorts in terms of R/P, PFS, or OS. The most common cause of death was disease relapse in both groups. In NHL patients eligible for allo-HCT, there was no difference in OS between the 2 cohorts. Age alone should not determine allo-HCT eligibility in NHL, and Medicare should expand allo-HCT coverage to older adults. 2020-04-29T05:50:32Z 2020-04-29T05:50:32Z 2018-04-23 2020-04-29T05:50:32Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 2473-9529 https://hdl.handle.net/2445/157959 696016 29685953 eng Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2018018531 Blood Advances, 2018, vol. 2, num. 8, p. 933-940 https://doi.org/10.1182/bloodadvances.2018018531 (c) American Society of Hematology, 2018 info:eu-repo/semantics/openAccess 8 p. application/pdf American Society of Hematology Articles publicats en revistes (Ciències Clíniques)